Table 4.

Association in VAS between nefopam group and control group regarding block.

No block
Variable	Total	Control Group	Nefopam Group	p-Value *
T 0 (preop)
VAS
mean ± SD	2 ± 0.73	2.02 ± 0.78	1.98 ± 0.69	0.942
median (range)	2 (0–4)	2 (0–4)	2 (0–3)
T 1 (0)
VAS
mean ± SD	5.37 ± 2.6	5.6 ± 2.71	5.13 ± 2.49	0.326
median (range)	6 (0–10)	6 (0–10)	6 (0–8)
T 2 (30 min)
VAS
mean ± SD	4.16 ± 2.09	4.09 ± 1.98	4.22 ± 2.22	0.906
median (range)	4 (1–8)	4 (2–8)	4 (1–8)
T 3 (12 h)
VAS
mean ± SD	4.13 ± 1.63	4.49 ± 1.67	3.78 ± 1.52	0.058
median (range)	4 (0–8)	5 (2–8)	4 (0–8)
T 4 (24 h)
VAS
mean ± SD	3.11 ± 1.18	3.18 ± 1.17	3.04 ± 1.19	0.85
median (range)	3 (0–6)	3 (1–6)	3 (0–5)
T 5 (48 h)
VAS
mean ± SD	2.41 ± 1.09	2.36 ± 0.98	2.47 ± 1.19	0.656
median (range)	2 (0–6)	2 (1–5)	2 (0–6)
Block
Variable	Total	Control Group	Nefopam Group	p-Value *
T 0 (preop)
VAS
mean ± SD	2 ± 0.86	1.93 ± 0.81	2.07 ± 0.91	0.635
median (range)	2 (0–4)	2 (0–3)	2 (0–4)
T 1 (0)
VAS
mean ± SD	1.3 ± 1.84	1.18 ± 1.91	1.42 ± 1.79	0.298
median (range)	0 (0–6)	0 (0–6)	1 (0–6)
T 2 (30 min)
VAS
mean ± SD	1.5 ± 1.68	1.29 ± 1.5	1.71 ± 1.84	0.291
median (range)	1 (0–7)	1 (0–6)	1 (0–7)
T 3 (12 h)
VAS
mean ± SD	2.74 ± 2.1	2.78 ± 2.2	2.71 ± 2.02	0.967
median (range)	3 (0–7)	3 (0–7)	3 (0–7)
T 4 (24 h)
VAS
mean ± SD	2.66 ± 1.44	2.91 ± 1.52	2.4 ± 1.32	0.03 *
median (range)	2.5 (0–7)	3 (0–6)	2 (0–7)
T 5 (48 h)
VAS
mean ± SD	2.28 ± 1.04	2.47 ± 1.16	2.09 ± 0.87	0.088
median (range)	2 (0–6)	2 (0–6)	2 (0–4)

Wilcoxon rank-sum test: mean ± SD, mean ± standard deviation; VAS, visual analogue scale. *, p < 0.05.